No Data
Alterity Surges After Mid-stage Trial Data for Lead Asset
Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth?
Athira Pharma to Pay $4 Million Over Alleged Research Misconduct
Express News | U.S. Justice Department Says Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act Allegations Related to Scientific Research Misconduct
Athira Pharma Insider Ups Holding By 111% During Year
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects Of ATH-1105 In Models Of ALS At Motor Neurone Disease Association's International Symposium On ALS/MND
browny_440 OP : might se a nice 20% rise next week
browny_440 OP : buy the dip that's incoming
browny_440 OP : maybe this week then lol